LAURUSLABS:NSE:NSE-Laurus Labs Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 470.25

Change

-4.45 (-0.94)%

Market Cap

USD 261.71B

Volume

1.23M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+5.40 (+0.29%)

USD 4,405.17B
DIVISLAB:NSE Divi's Laboratories Limited

+2.95 (+0.05%)

USD 1,427.11B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+13.25 (+0.38%)

USD 1,137.04B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-4.10 (-0.06%)

USD 1,107.90B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-3.70 (-0.35%)

USD 1,061.98B
MANKIND:NSE Mankind Pharma Ltd

+84.05 (+3.17%)

USD 1,020.50B
LUPIN:NSE Lupin Limited

+33.50 (+1.54%)

USD 1,014.97B
AUROPHARMA:NSE Aurobindo Pharma Limited

+20.20 (+1.36%)

USD 871.87B
ALKEM:NSE Alkem Laboratories Limited

+64.35 (+1.08%)

USD 728.94B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-14.95 (-0.87%)

USD 464.59B

ETFs Containing LAURUSLABS:NSE

EPU iShares MSCI Peru ETF 2.69 % 0.59 %

+1.55 (+0%)

USD 0.08B
EEMS iShares MSCI Emerging Mar.. 0.00 % 0.67 %

+1.03 (+0%)

N/A
LERN:F 0.00 % 0.00 %

N/A

N/A
LERN:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.59% 28% F 35% F
Dividend Return 0.09% 5% F 5% F
Total Return 8.68% 27% F 34% F
Trailing 12 Months  
Capital Gain 22.05% 24% F 36% F
Dividend Return 0.21% 12% F 13% F
Total Return 22.26% 23% F 36% F
Trailing 5 Years  
Capital Gain 541.28% 84% B 77% C+
Dividend Return 9.30% 78% C+ 61% D-
Total Return 550.58% 84% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 92.63% 92% A 87% B+
Dividend Return 93.22% 92% A 87% B+
Total Return 0.60% 60% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 163.55% 4% F 6% D-
Risk Adjusted Return 57.00% 50% F 34% F
Market Capitalization 261.71B 79% B- 85% B

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.